BioSpace News Archive

Cerner Corporation (Nasdaq: CERN) announced today that Chairman and CEO Brent Shafer, President Don Trigg and Executive Vice President and Chief Financial Officer Marc Naughton will present at the 39 th Annual J.P. Morgan Healthcare Conference. The presentation will begin at 10:00 a.m. EST on Jan. 13, and will be available live and archived on Cerner’s website in the Investor Relations section. The presentation may include discussion o

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7, 2021 at 4:00 p.m. E

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. Presentation Details The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:0

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today plans to progress its gene therapy and gene editing platform, and unveiled plans to have three clinical programs and a development candidate in a new therapeutic area during 2021.

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer.

CorWave reported today it has raised $40M from returning investors and three new investors. The company is developing an implantable heart pump (Left Ventricular Assist Device, LVAD) based on a breakthrough technology: the wave membrane pump . These new funds will enable CorWave to finalize development of its initial product, expand a manufacturing infrastructure, complete regulatory testing required to conduct human

Successful additions of ERAS-601 and ERAS-007, potential best-in-class inhibitors of SHP2 and ERK, respectively, enable “MAPK Clamp” approach to shut down RAS/MAPK pathway Erasca doses first patient in FLAGSHP-1 study, Erasca’s first clinical trial

Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data for VAX-A1, the Company’s novel Group A Streptococcus (Group A Strep) conjugate vaccine candidate, in the journal Infectious Microbes & Diseases . Group A Strep is

ReWalk Robotics Ltd. announced that it has repaid in full the outstanding balance on its credit line from Kreos Capital V Limited.

Panalgo’s IHD software to be used by the EMA to rapidly answer questions around drug safety and efficacy and better understand real-world medication use